A proposal for a shorter post-exposure prophylaxis of HIV infection to prevent adverse secondary reactions.
Bijlenga
G
G
D000818:Animals; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D004334:Drug Administration Schedule; D006678:HIV / Q000276:immunology; D015483:HIV Antibodies / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control* / Q000635:transmission; D006679:HIV Seropositivity / Q000188:drug therapy / Q000635:transmission; D006801:Humans; D011818:Rabies / Q000517:prevention & control
D019380:Anti-HIV Agents; D015483:HIV Antibodies